PHAT — Phathom Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1783183 ·
Last close
$7.35
Market Cap
$594.62M
52W High
$18.31
52W Low
$6.91
ADV30
1,202,730
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 74,274,000 | 59,178,000 | -3,965,000 | -17,582,000 | 327,075,000 | 182,478,000 | 671,348,000 |
| Mar 2026 | 58,301,000 | 46,305,000 | -15,477,000 | -30,369,000 | 305,120,000 | 180,904,000 | 642,075,000 |
| Dec 2025 | 57,584,000 | 49,936,000 | -5,928,000 | -21,148,000 | 259,149,000 | 129,972,000 | 697,318,000 |
| Sep 2025 | 49,504,000 | 43,314,000 | -15,271,000 | -29,973,000 | 240,289,000 | 135,156,000 | 662,823,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,693,000
Investing CF
$-219,000
Financing CF
$69,823,000
CapEx
$-219,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.28
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,532,209,000
Inventory
$7,713,000
Receivables
$97,422,000
ST Investments
—
EBIT TTM
$-35,645,000
Pretax Income TTM
$-99,072,000
Interest Exp TTM
$63,427,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$239,662,000
EBITDA
$-40,134,000
Free Cash Flow
$-32,627,124
Enterprise Value
$1,045,877,632
Total Cash
$182,478,000
Total Debt
$552,024,000
Shares Out
80,900,934
Trailing EPS
$-1.25
Book Value
$-4.30
ROE
—
ROA
-8.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 175,110,000 | -159,986,000 | -221,247,000 | 259,149,000 | 697,318,000 | -438,169,000 | -166,775,000 |
| Dec 2024 | 55,252,000 | -277,467,000 | -334,326,000 | 378,318,000 | 631,898,000 | -253,580,000 | -266,770,000 |
| Dec 2023 | 682,000 | -167,312,000 | -201,592,000 | 413,842,000 | 486,601,000 | -72,759,000 | -137,580,000 |
| Dec 2022 | 0 | -172,440,000 | -197,723,000 | 164,810,000 | 239,624,000 | -74,814,000 | -146,530,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.08
Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $7.35 · call volume: 33 · put volume: 115
Expected Move to 2028-01-21:
±$6.69
(91.02%) —
implied range
$0.66 –
$14.04
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | $596.18M | $4.75 | — |
| CTMX | CytomX Therapeutics, Inc. | $586.15M | $2.69 | — |
| IBO | IMPACT BIOMEDICAL INC. | $604.88M | $5.61 | — |
| SGMT | Sagimet Biosciences Inc. | $612.22M | $9.94 | — |
| ALT | Altimmune, Inc. | $575.77M | $2.96 | — |
News headlines (Yahoo Finance, 1h cache)
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival
2026-09-09 17:26 · Yahoo
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?
2026-07-30 22:09 · Yahoo
Phathom Pharmaceuticals Q2 Earnings Call Highlights
2026-07-30 19:04 · Yahoo
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
2026-07-30 14:30 · Yahoo
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
2026-07-20 12:00 · Yahoo
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
2026-06-23 11:59 · Yahoo
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-22 12:00 · Yahoo
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
2026-05-20 12:00 · Yahoo
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks
2026-05-03 10:08 · Yahoo
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline
2026-05-05 10:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.